guest ::
| Home > Publications database > MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. > print |
| Home > Publications database > MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. > print |
| 001 | 180368 | ||
| 005 | 20240229145616.0 | ||
| 024 | 7 | _ | |a 10.1186/s40364-022-00389-x |2 doi |
| 024 | 7 | _ | |a pmid:35715818 |2 pmid |
| 024 | 7 | _ | |a altmetric:130374665 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-01282 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Catanzaro, Giuseppina |b 0 |
| 245 | _ | _ | |a MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. |
| 260 | _ | _ | |a London |c 2022 |b Biomed Central |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655727742_1692 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool.We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres.These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways.Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Pediatric low-grade gliomas |2 Other |
| 650 | _ | 7 | |a Personalized medicine |2 Other |
| 650 | _ | 7 | |a Prognostic biomarker |2 Other |
| 650 | _ | 7 | |a Risk stratification |2 Other |
| 650 | _ | 7 | |a Tumour progression |2 Other |
| 650 | _ | 7 | |a miR-1248 |2 Other |
| 700 | 1 | _ | |a Besharat, Zein Mersini |b 1 |
| 700 | 1 | _ | |a Carai, Andrea |b 2 |
| 700 | 1 | _ | |a Jäger, Natalie |0 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3 |b 3 |u dkfz |
| 700 | 1 | _ | |a Splendiani, Elena |b 4 |
| 700 | 1 | _ | |a Colin, Carole |b 5 |
| 700 | 1 | _ | |a Po, Agnese |b 6 |
| 700 | 1 | _ | |a Chiacchiarini, Martina |b 7 |
| 700 | 1 | _ | |a Citarella, Anna |b 8 |
| 700 | 1 | _ | |a Gianno, Francesca |b 9 |
| 700 | 1 | _ | |a Cacchione, Antonella |b 10 |
| 700 | 1 | _ | |a Miele, Evelina |b 11 |
| 700 | 1 | _ | |a Diomedi Camassei, Francesca |b 12 |
| 700 | 1 | _ | |a Gessi, Marco |b 13 |
| 700 | 1 | _ | |a Massimi, Luca |b 14 |
| 700 | 1 | _ | |a Locatelli, Franco |b 15 |
| 700 | 1 | _ | |a Jones, David |0 P:(DE-He78)551bb92841f634070997aa168d818492 |b 16 |u dkfz |
| 700 | 1 | _ | |a Figarella-Branger, Dominique |b 17 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 18 |u dkfz |
| 700 | 1 | _ | |a Mastronuzzi, Angela |b 19 |
| 700 | 1 | _ | |a Giangaspero, Felice |b 20 |
| 700 | 1 | _ | |a Ferretti, Elisabetta |b 21 |
| 773 | _ | _ | |a 10.1186/s40364-022-00389-x |g Vol. 10, no. 1, p. 44 |0 PERI:(DE-600)2699926-2 |n 1 |p 44 |t Biomarker Research |v 10 |y 2022 |x 2050-7771 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:180368 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)551bb92841f634070997aa168d818492 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 18 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-06-15 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-06-15 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-06-15 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-06-15 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-06-15 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOMARK RES : 2021 |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-02-14T16:19:51Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-02-14T16:19:51Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-02-14T16:19:51Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-19 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-19 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b BIOMARK RES : 2021 |d 2022-11-19 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)B360-20160331 |k B360 |l Pediatric Glioma |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B360-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|